Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC. - Form 4

BRAINSTO Form 4 June 23, 20	ORM CELL THE	RAPEUTI	CS INC	2.					
FORN Check t	1 4 _{UNITED}	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					OMB Number:	PPROVAL 3235-0287 January 31,	
if no los subject Section Form 4 Form 5 obligati may co <i>See</i> Inst 1(b).	to 16. or Filed pu ons ntinue. ruction	on 30(h) of the Investment Company Act of 1940						Expires: Estimated burden hou response	2005 average urs per
(Print or Type	Responses)								
1. Name and Pinkas Alc	2. Issuer Name and Ticker or Trading Symbol BRAINSTORM CELL THERAPEUTICS INC. [BCLI]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) C/O BRAI THERAPE UNIVERS SUITE 320	3. Date of Earliest Transaction(Month/Day/Year)06/22/2016				XDirector10% Owner Officer (give titleOther (specify below)				
	(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person		
HACKEN	Form filed by M Person					fore than One Reporting			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed o	f, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4	(A) or of (D)	SecuritiesIBeneficially(Owned(6. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Re	eport on a separate lin	e for each cl	ass of sec	Code V urities bene	Perso inforn requir	ned directly on s who rest nation cont red to response		are not m	SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 2. 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 4. 7. Title and Amount of Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative **Expiration Date** Underlying Securities Security or Exercise any Code Securities (Month/Day/Year) (Instr. 3 and 4) (Instr. 3) Price of (Month/Day/Year) (Instr. 8) Acquired (A) Derivative or Disposed of Security (D) (Instr. 3, 4, and 5) Amount Expiration or Date Exercisable Title Date Number Code V (A) (D) of Share Stock Option Common \$ 0.75 06/22/2016 15,333 07/22/2016(1) 06/22/2026 15,33 Α Stock (right to buy) **Reporting Owners** Relationships **Reporting Owner Name / Address** 10% Owner Officer Other Director Pinkas Alon C/O BRAINSTORM CELL THERAPEUTICS INC. Х 3 UNIVERSITY PLAZA DRIVE, SUITE 320 HACKENSACK, NJ 07601 **Signatures** /s/ Thomas B. Rosedale (Pursuant to Power of 06/23/2016 Attorney)

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC. - Form 4

**Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on July 22, 2016 until fully vested and exercisable on June 22, 2017, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

Date

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.